vimarsana.com

Latest Breaking News On - Dainippon sumitomo pharma - Page 1 : vimarsana.com

Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies

Objective To systematically assess credibility and certainty of associations between cannabis, cannabinoids, and cannabis based medicines and human health, from observational studies and randomised controlled trials (RCTs). Design Umbrella review. Data sources PubMed, PsychInfo, Embase, up to 9 February 2022. Eligibility criteria for selecting studies Systematic reviews with meta-analyses of observational studies and RCTs that have reported on the efficacy and safety of cannabis, cannabinoids, or cannabis based medicines were included. Credibility was graded according to convincing, highly suggestive, suggestive, weak, or not significant (observational evidence), and by GRADE (Grading of Recommendations, Assessment, Development and Evaluations) (RCTs). Quality was assessed with AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews 2). Sensitivity analyses were conducted. Results 101 meta-analyses were included (observational=50, RCTs=51) (AMSTAR 2 high 33, moderate 31, low 32,

Nortriptyline Market | Dainippon Sumitomo Pharma, EU-Pharma, Eli Lilly and Company

Global Cancer Vaccine Partnering Terms and Agreements Analysis Report/Directory 2023: Access Over 350 Cancer Vaccine Deals - Disclosed Headlines, Upfronts, Milestones and Royalties

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.